A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: Pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand

• Main Authors: Vanprapar N., Cressey T.R., Chokephaibulkit K., Muresan P., Plipat N., Sirisanthana V., Prasitsuebsai W., Hongsiriwan S., Chotpitayasunondh T., Eksaengsri A., Toye M., Smith M.E., McIntosh K., Capparelli E., Yogev R.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-77957278518&partnerID=40&md5=922bd14f213bb00e000de73c38274a27; http://cmuir.cmu.ac.th/handle/6653943832/855
• Institution: Chiang Mai University

Background: Pediatric fixed-dose combinations (FDCs) are needed to facilitate antiretroviral therapy in children. We evaluated the relative bioavailability, safety, and therapeutic adequacy of a novel chewable pediatric FDC tablet of stavudine (7 mg), lamivudine (30 mg), and nevirapine (50 mg), refe...